BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Elite Pharmaceuticals to Host Conference Call to Discuss Second Quarter Financial Results on September 10, 2017

  Stockholder questions should be summited to the company in advance of the call.

  November 7, 2017

   · 

  3 min read
• Drug Development

  Krystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa

  The drug is currently in preclinical development for dystrophic epidermolysis bullosa, or DEB.

  November 7, 2017

   · 

  4 min read
• Drug Development

  DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials

  The study was designed to compare the profile of DM199 to that of the approved urinary KLK1 product (trade name Kailikang) on the market in Asia for acute ischemic stroke.

  November 7, 2017

   · 

  5 min read
• Business

  Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress

  In the three months ended Sept. 30, 2017 and 2016, we recognized $1.9 million and $1.3 million, respectively, of revenue associated with our Pfizer collaboration.

  November 7, 2017

   · 

  11 min read
• Business

  Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B

  Spark Therapeutics to receive up to an additional $25 million per terms of amendment.

  November 7, 2017

   · 

  8 min read
• Business

  Repligen Extends Long Term Supply Agreement With Purolite for Protein A Ligands

  Pursuant to the agreement, Repligen will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025.

  November 7, 2017

   · 

  4 min read
• Drug Development

  ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase IIb Clinical Trial of OBE2109 for the Treatment of Endometriosis

  Approximately 330 patients are expected to be randomized in the EDELWEISS clinical trial, and primary endpoint efficacy results continue to be anticipated in mid-2018.

  November 7, 2017

   · 

  5 min read
• Business

  Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update

  For the third quarter of 2017, the company’s total revenue was less than $0.1 million, which compares with $1.0 million for the third quarter of 2016.

  November 7, 2017

   · 

  16 min read
• Business

  Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results

  Approximately 24,900 Auryxia prescriptions were written in the third quarter of 2017, representing 18 percent growth over the second quarter of 2017.

  November 7, 2017

   · 

  12 min read
• Business

  Antares Pharma Reports Third Quarter 2017 Operating and Financial Results

  The Company reported record revenue of $15.1 million and a net loss per share of $0.03 for the three months ended September 30, 2017.

  November 7, 2017

   · 

  12 min read